Research & Development
MDxHealth is the leader in molecular diagnostics for urologic cancer research with a proven track record to identify, develop, validate and deliver molecular diagnostic assays for prostate cancer. Leveraging our proprietary portfolio of genes, we are building a robust portfolio of biomarkers for diagnostic, prognostic and predictive molecular assays for urology. In addition, MDxHealth has numerous proprietary biomarkers for other solid cancer types ready for development.
We endeavor to stay at the cutting edge of molecular diagnostics by continuously exploring and developing new and improved clinically relevant products, approaches and techniques. Since 2010, when we first announced the transition in our business model from a research and licensing company to a commercial clinical diagnostic company, we have been rationalizing our R&D efforts with the goal to narrow our focus on select number of core development projects to bring to the market. With our current focus on urologic cancers, we have either delayed, partnered or suspended many of our development programs previously identified in our product pipeline.
Our ongoing core research and development efforts include:
- Further enhancements of our ConfirmMDx and SelectMDx for Prostate Cancer tests
- Identification and development of new prostate cancer biomarkers
- Technology platform development to increase throughput and economic efficiencies in our testing and laboratory operations
Our research and development efforts are not limited to specific technology platforms, biomarkers or methodologies. We seek to leverage current and future innovations in biomarker identification and measurement in developing future solutions. Over the past decade, MDxHealth has assembled a world-class scientific team and acquired unique experience in the application of Next-Generation and Deep Sequencing technologies for the identification and validation of powerful epigenetic biomarkers.
Enhancement of ConfirmMDx for Prostate Cancer Test
In addition to our ongoing and planned clinical studies to further support the negative predictive value (NPV) of our ConfirmMDx test, we have committed significant resources to further establish the actionability of a positive ConfirmMDx test result.
Although the ConfirmMDx test was developed to help reduce unnecessary repeat biopsies, by virtue of its high NPV, the test was also shown to be the most significant independent predictor for prostate cancer detection on repeat biopsy as reported in multiple clinical validation studies. To further enhance the clinical utility of a positive test result, a risk score for ConfirmMDx methylation-positive men was developed to increase the positive predictive value (PPV), especially for those potentially harboring aggressive prostate cancer. A combined risk score based on clinical risk factors combined with epigenetic profiling strongly correlates with the detection of aggressive prostate cancer upon repeat biopsy.
At the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, USA (January 30 – February 1, 2014), MDxHealth presented data demonstrating that epigenetic profiling of selected genes provided prognostic information, corresponding to Gleason score that could help to identify patients with aggressive prostate cancer. The results were reported on a selected panel of genes that MDxHealth had previously identified as exhibiting prognostic value, including the GSTP1, APC and RASSF1 genes from the ConfirmMDx for Prostate Cancer test.
At the 2015 ASCO Genitourinary Cancers Symposium in Orlando, USA (February 26-28, 2015), MDxHealth and our collaborators presented data demonstrating that the intensity of field effect hypermethylation of GSTP1, APC and RASSF1 in benign biopsy cores correlates with the level of hypermethylation present in the cancer cores from the same patient. In Gleason score 6 (GS6) cancer cores, the intensity of hypermethylation is higher in subjects who also have cores of GS7 than in subjects with GS6 cores only. These findings support the utility of an algorithm that is sensitive to the aggressiveness of undetected prostate cancer.
MDxHealth and our collaborators presented additional scientific and clinical data describing a risk score for ConfirmMDx methylation positive patients at the 2015 Annual American Urological Association meeting in New Orleans, USA (May 15-19, 2015). The data support a secondary algorithm, which combines clinical risk factors with epigenetic profiling to improve the identification of patients with a negative prostate biopsy but who may be at increased risk of harboring clinically significant prostate cancer.
MDxHealth and Exact Sciences have entered into a collaborative agreement to share proprietary technologies arising from their respective ground-breaking discovery and development efforts in the fields of epigenetics and molecular diagnostics. Exact Sciences also acquired MDxHealth patents directed toward colorectal cancer, including its DNA methylation biomarker, NDRG4, as well as technology covering the use of FIT (fecal immunochemical test) in combination with methylation. Exact Sciences obtained FDA approval and CMS coverage, and launched its Cologuard® test.
MDxHealth holds exclusive rights to the MGMT biomarker, which has been extensively studied in glioblastoma and related brain cancers. Studies on thousands of clinical trial patients have demonstrated that methylation of MGMT can help oncologists identify newly diagnosed glioblastoma patients that are likely to respond to the most commonly used class of brain cancer drugs (alkylating agents). MDxHealth’s PredictMDx for Glioblastoma (MGMT) test was included in the National Comprehensive Cancer Network (NCCN) Senior Adult Oncology Guidelines and has been awarded a Tier 1 reimbursement code, 81287, by American Medical Association (AMA), which provides a clear basis for comprehensive reimbursement. MDxHealth’s strategy has been to partner with leading pathology service providers, such as the Laboratory Corporation of America (LabCorp) to distribute the MGMT test to clinicians.
MDxHealth, in collaboration with the University of Gent in Belgium, has established the NXTGNT (Epi)genomics research joint-venture, which brings together researchers with expertise in genomic and methylome sequencing and bioinformatics. The Laboratory for Bio-informatics and Computational Genomics (BIOBIX, FBW), the laboratory for Pharmaceutical Biotechnology (FFW), the IOF consortium Biomarkers, together with a research team from MDxHealth are located within the Faculty of Pharmaceutical Sciences at the University of Gent in Belgium. NXTGNT’s core focus is the application of innovative technologies such as NextGen and Deep Targeted Sequencing for the discovery of novel biomarkers which improve the diagnosis and risk stratification of cancer patients, as well as the identification of potential targets for therapy. The mission is to accelerate the development and preclinical validation of new diagnostic and therapeutic products for personalized medicine.
Utilizing our experience in the development of methylation-specific deep sequencing technology, MDxHealth offers Epihealth testing to researchers and pharmaceutical companies. EpiHealth is a panel of hundreds of defined genes whose expression is controlled by DNA methylation. This concise panel allows collaborators to test xenografts, cell lines and primary material, and to focus on known published genes thereby decreasing the overall project development time. Knowledge gained from the profiles of the primary material allow for rapid downstream development of methylation-specific PCR assays for clinical application.